The trial involves people who have long‑standing rhinitis or rhinoconjunctivitis, conditions that cause a runny or itchy nose and eyes, and who may also have mild‑to‑moderate asthma that is well controlled. These symptoms are triggered by allergens that cause IgE mediated allergies. To evaluate the allergy status, a series of solutions containing specific pollen extracts are used: parietaria judaica pollen extract (code SPT‑RX‑PAR), phleum pratense pollen extract (SPT‑RX‑PHL), betula pendula pollen extract (SPT‑RX‑BET), dermatophagoides pteronyssinus extract (SPT‑RX‑DPT), and olea europaea pollen extract (SPT‑RX‑OLE). Each solution is applied to the skin in a small amount for a diagnostic test.
The purpose of the study is to assess how well these extracts identify allergic versus non‑allergic individuals by measuring the test’s sensitivity and specificity. Participants will attend a clinic visit where a tiny amount of each solution is placed on the forearm and gently pricked into the skin using a skin prick test method; a control drop without allergen is also used. After a few minutes the size of any raised, red bump (called a wheal) is measured, and the results are compared with the person’s medical history to determine accuracy. The study follows participants for a short period after the test to complete the assessments.



Germany
Spain